摘要
目的 为提高血站供血安全性 ,探讨核酸扩增检测在血站血液筛查中的可行性。方法 在酶联免疫吸附试验 (ELISA)常规筛查血液的基础上 ,采用荧光定量聚合酶链反应 (PCR)方法 ,检测乙型肝炎表面抗原 (HBsAg)、丙型肝炎抗体 (抗 HCV)和人免疫缺陷病毒抗体 (抗 HIV) 1/ 2呈阴性的献血者微量血浆汇集池标本 (2 0人份× 5 0 μl汇集 )中的丙肝病毒 (HCV)和乙肝病毒 (HBV)核酸 ,再对阳性汇集池中的标本进行单份检测。结果 880 5份 (分 44 2个汇集池 )血液被检测HCVRNA ,结果有1例 (0 .0 1% )为阳性 ;144 1份血液被检测HBVDNA ,结果 6例 (0 .4% )为阳性。从标本汇集到筛查出单份阳性献血者大约需要 3d。结论 ELISA结合荧光定量PCR检测微量血浆汇集池标本的方法筛查血液HBV和HCV感染是可行的 。
Objectives To increase the safety of blood supply and to evaluate the feasibility of Nucleic Acid amplification test (NAT) of blood donations in blood bank. Methods Individual donor plasma samples serologically negative for HCV, HBV and HIV detected by ELISA were pooled according to the size of 20×50 μl. HCV RNA and HBV DNA in pooled samples were detected by AcuGen AG 9600 AmpliSensor qualitative PCR methods. Individual donor plasma samples in positive pooled samples were further tested by PCR. Results One(0.01%)of 8805 donations was PCR for HCV RNA positive. Six (0.4%)of 1 441 donations were PCR for HBV DNA positive. The whole procedure took three days from pooling donor plasma samples to identifying the positive samples. Conclusion It is feasible to incorporate NAT into ELISA screening blood donations for HBV and HCV. NAT will further increase the safety of blood supply.
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2001年第3期141-143,共3页
Chinese Journal of Laboratory Medicine
